Next Generation Sequencing (NGS) has become a powerful tool to decipher the genetic code. It is often seen as having revolutionized genomic research and is used daily in research and diagnostic labs. Nowadays it is used to detect the sequence of genomes, exomes or specific regions; it can provide information about copy number, translocations or the entire transcriptome.
However, while numerous applications have been developed, there have been limited choices when it comes to sequencing platforms. This limited choice has had consequences, none of which have been positive for researchers, clinical practitioners or – ultimately – patients.
Thankfully, the sequencing landscape is changing, and with recent developments and a rapidly developing patent landscape, we look set for an exciting period of innovation, new products, new possibilities and – importantly – more choice.
– – – – –
What this webinar will cover
During this webinar we will introduce MGI, a company committed to being a world-leading life science innovator, and their new commercial sequencing chemistry, HotMPS*, utilizing their existing DNBSEQ platforms**.
Not only will we cover the technical advantages of this new game-changing sequencing chemistry*, but we will also present a case study that outlines a research group’s experience of using it to deliver new, ground-breaking gene expression profiling research.
– – – – –
Presentations and speakers
TALK 1: Nathaniel Evans, Field Application Scientist at MGI will give some background information about the technology and the newly developed sequencing chemistry*.
TALK 2: Dr Szatmári István, Head of Genomic Medicine and Bioinformatics Core Facility, University of Debrecen, will provide data generated in his lab to show the power of this new chemistry* in his presentation, titled: Runx3- and Zbtb46-dependent gene expression profiling with DNBSEQ G400**.
Talks will be followed by a live Q&A session.
– – – – –
What you will take away from this webinar
You will leave this webinar with:
- A better understanding of the DNBSEQ technology and its advantages
- An introduction to the new sequencing chemistry: HotMPS*
- First-hand impressions from a core facility comparing different sequencing chemistries
– – – – –
– – – – –
This webinar has been produced with the kind support of MGI. You can find out more about the DNBSEQ technology and the HotMPS sequencing chemistry* outlined in this webinar by visiting the MGI website.
* This sequencing reagent is only available in selected countries.
** This sequencer is only available in selected countries, and its software has been specially configured to be used in conjunction with MGI’s HotMPS sequencing reagents exclusively.
*** Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria and Romania. No purchase orders for StandardMPS products will be accepted in the USA until after January 1, 2023.
Nathaniel Evans is UK Field Application Scientist for MGI, which he joined in the summer of 2022. He completed his MSc in Synthetic Biology at the University of Edinburgh in 2020 before joining Illumina as a Technical Applications Scientist. Apart from experience in the NGS sector, he has experience working in the medical device field (Dexcom), IT (PMC), as well as having worked in Canada for two years.
Istvan Szatmari is an Associate Professor at Department of Biochemistry and Molecular Biology, University of Debrecen, Hungary. He is also the Head of Genomic Medicine and Bioinformatics Core Facility at the same institution. He participates in stem cell research, with his research team especially focusing on embryonic stem cell-derived dendritic cell development, via transcription factor-mediated cellular programming.